Diamyd Medical AB (publ) (DMYD-B) - Total Liabilities
Based on the latest financial reports, Diamyd Medical AB (publ) (DMYD-B) has total liabilities worth Skr70.82 Million SEK (≈ $7.62 Million USD) as of November 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore cash efficiency ratio of Diamyd Medical AB (publ) to assess how effectively this company generates cash.
Diamyd Medical AB (publ) - Total Liabilities Trend (2010–2025)
This chart illustrates how Diamyd Medical AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Check how resilient are Diamyd Medical AB (publ)'s assets to evaluate the company's liquid asset resilience ratio.
Diamyd Medical AB (publ) Competitors by Total Liabilities
The table below lists competitors of Diamyd Medical AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Floyd Public Company Limited
BK:FLOYD
|
Thailand | ฿176.16 Million |
|
Australian Agricultural Projects Ltd
AU:AAP
|
Australia | AU$8.54 Million |
|
Opus One Resources Inc
V:OOR
|
Canada | CA$812.34K |
|
G3 Global Bhd
KLSE:7184
|
Malaysia | RM11.84 Million |
|
Reading International B Inc
NASDAQ:RDIB
|
USA | $448.20 Million |
|
Saudee Group Bhd
KLSE:5157
|
Malaysia | RM8.41 Million |
|
LogProstyle Inc.
NYSE MKT:LGPS
|
USA | $21.24 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Diamyd Medical AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Diamyd Medical AB (publ) worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 9.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 8.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Diamyd Medical AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Diamyd Medical AB (publ) (2010–2025)
The table below shows the annual total liabilities of Diamyd Medical AB (publ) from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-08-31 | Skr72.64 Million ≈ $7.82 Million |
+2.14% |
| 2024-08-31 | Skr71.12 Million ≈ $7.65 Million |
+95.32% |
| 2023-08-31 | Skr36.41 Million ≈ $3.92 Million |
+64.42% |
| 2022-08-31 | Skr22.14 Million ≈ $2.38 Million |
+81.83% |
| 2021-08-31 | Skr12.18 Million ≈ $1.31 Million |
-29.50% |
| 2020-08-31 | Skr17.28 Million ≈ $1.86 Million |
+51.24% |
| 2019-08-31 | Skr11.42 Million ≈ $1.23 Million |
-4.56% |
| 2018-08-31 | Skr11.97 Million ≈ $1.29 Million |
-0.10% |
| 2017-08-31 | Skr11.98 Million ≈ $1.29 Million |
+40.70% |
| 2016-08-31 | Skr8.52 Million ≈ $916.35K |
+19.58% |
| 2015-08-31 | Skr7.12 Million ≈ $766.33K |
+3.80% |
| 2014-08-31 | Skr6.86 Million ≈ $738.25K |
-8.83% |
| 2013-08-31 | Skr7.52 Million ≈ $809.70K |
-38.13% |
| 2012-08-31 | Skr12.16 Million ≈ $1.31 Million |
-79.26% |
| 2011-08-31 | Skr58.63 Million ≈ $6.31 Million |
-76.96% |
| 2010-08-31 | Skr254.41 Million ≈ $27.38 Million |
-- |
About Diamyd Medical AB (publ)
Diamyd Medical AB (publ) develops precision medicine therapies for the treatment of autoimmune diabetes. The company develops Diamyd, an antigen-specific immunotherapy, which is in phase III clinical trial for the treatment of type 1 diabetes and latent autoimmune diabetes in adults (LADA); and Remygen, an immunomodulation therapy, that is in phase I/II clinical trial for the treatment of with ty… Read more